Related Experiment Video
Updated: Sep 13, 2025

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Regulation, effects and monitoring of compartmented cGMP signalling in cardiomyocytes-current status
Kjetil Wessel Andressen1, Daiana Sedneva-Lugovets1, Mette Ovesen1
1Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.
Insights
Compartmented cyclic guanosine 3
Area of Science:
- Cardiovascular Biology
- Cellular Signalling
- Molecular Cardiology
Background:
- Cyclic guanosine 3',5'-monophosphate (cGMP) signalling is compartmentalized in cardiomyocytes.
- This compartmentalization influences cardiac physiology and pathophysiology.
Purpose of the Study:
- To review the regulation and monitoring of compartmented cGMP signalling in cardiomyocytes.
- To highlight recent advancements in methodologies for studying cGMP dynamics.
Main Methods:
- Utilized fluorescence resonance energy transfer (FRET)-based biosensors for visualizing cGMP dynamics.
- Emphasized the role of guanylyl cyclases (GCs) and phosphodiesterases (PDEs) in regulating cGMP pools.
- Focused on subcellular localization of GCs and PDEs in defining signalling compartments.
Main Results:
- Distinct cGMP pools are produced by particulate (GC-A, GC-B) and soluble (sGC) guanylyl cyclases.
- Phosphodiesterases (PDEs) maintain intracellular cGMP gradients.
- FRET biosensors revealed localized cGMP signals and discrete signalling compartments.
Conclusions:
- Understanding compartmented cGMP signalling is crucial for treating cardiac dysfunction.
- New tools are improving the visualization of cGMP dynamics.
- This research may lead to novel therapeutic strategies for cardiovascular diseases.
Abstract:
Cyclic guanosine 3',5'-monophosphate (cGMP) signalling in cardiomyocytes is intricately organized within cellular compartments, influencing several physiological and pathophysiological processes in the heart. We review how compartmented cGMP signalling is regulated and can be monitored within cardiomyocytes, emphasizing recent advances and methodologies. Three different guanylyl cyclases (GCs), two particulate (GC-A and GC-B) and one soluble (sGC), produce distinct cGMP pools, giving rise to differential signalling in cardiomyocytes. Phosphodiesterases (PDEs) maintain intracellular cGMP gradients. The use of intracellular biosensors, particularly those based on fluorescence resonance energy transfer (FRET), has enabled visualization of cGMP dynamics with high spatial and temporal resolution. These tools, which are constantly being improved, allow the observation of localized cGMP signals and have revealed discrete signalling compartments regulated by the subcellular localization of GCs and PDEs. Understanding these complex signalling networks in cardiomyocytes of healthy and diseased hearts can guide potential therapeutic approaches to treat cardiac dysfunction, including hypertrophy and heart failure. In conclusion, new tools are refining our understanding of compartmented cGMP signalling, which may lead to novel strategies for targeted therapeutic interventions in cardiovascular diseases.
Related Concept Videos
G-Protein Gated Ion Channels
Sensory...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
GPCRs Regulate Adenylyl Cylase Activity
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Cardiac Performance

